Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Google Secures Pentagon AI Deal for Classified Projects 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
SYDNEY, Australia, April 28, 2017 -- Parnell Pharmaceuticals Holdings Ltd (OTC:PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, provides notice of its Annual General Meeting to be held Monday 29 May 2017 at 4:00 p.m. (Central Standard Time) and Tuesday 30 May 2017 at 7:00 a.m. (Australian Eastern Standard Time)
NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM
Notice is given that the Annual General Meeting of shareholders of Parnell Pharmaceuticals Holdings Ltd (Company) will be held on:
Monday 29 May 2017 at 4:00 p.m. (Central Standard Time) and Tuesday 30 May 2017 at 7:00 a.m. (Australian Eastern Standard Time)
Meeting to be held by teleconference (Dial-in details below):
| United States | 1 800 444 2801 | |
| Australia | 02 9037 8402 | |
| New Zealand | 0 800 440 176 | |
| Switzerland | 0800 564 606 | |
| Netherlands | 8000 220 915 | |
| United Kingdom | 0 800 234 6984 | |
| Hong Kong | 800 903 191 | |
| Participant Code: 5687312 | ||
For a link to the full Notice of Annual General Meeting and Explanatory Memorandum please click:
http://www.globenewswire.com/NewsRoom/AttachmentNg/9bf785e5-da8b-4b60-a5d2-d71ace68e95e
______________________
26 April 2017
Dear Shareholder,
On behalf of the Board of Directors of Parnell Pharmaceuticals Holdings Limited (ACN 137 904 413) (Company), I invite you to join us at our Annual General Meeting (AGM), which has been scheduled as follows:
| Date: | 29 May 2017 (CST), 30 May 2017 (AEST) | |
| Time: | 4:00 p.m. (CST), 7:00 a.m. (AEST) | |
| Venue: | Held by telephone conference (dial-in details above) or by physical attendance at: | |
| Unit 4 Century Estate, 476 Gardeners Road, Alexandria, NSW, 2015 |
Outline of the items of business
At this AGM, we will provide an opportunity for shareholders to consider the following:
- the Company’s financial statements and related documents;
- ratification of the appointment of the Company auditor; and
- re-election of Dr. Alan Bell as a director of the Company.
Details of these items are contained in the enclosed Notice of AM and Explanatory Memorandum.
Voting at the AGM or by proxy
A proxy form accompanies the enclosed Notice of AGM. If you wish to attend the AGM in person, please bring a copy of the proxy form with you. Registration will be available from 3:30 p.m. (CST). If you are unable to attend in person, I encourage you to appoint a proxy to vote on the resolutions contained in the Notice of AGM on your behalf, by completing and returning the enclosed proxy form. Details of how to submit the proxy form are included with the form.
On behalf of all of the Directors, we look forward to hearing from you at the AGM.
Yours sincerely,
Alan Bell
Chairman
For more information, contact: Parnell Pharmaceuticals Holdings Robert Joseph, 913-274-2100 [email protected] Brad McCarthy, 913-274-2100 [email protected]
